443 related articles for article (PubMed ID: 33350309)
1. Structure-Based Screening to Discover New Inhibitors for Papain-like Proteinase of SARS-CoV-2: An
Jamalan M; Barzegari E; Gholami-Borujeni F
J Proteome Res; 2021 Jan; 20(1):1015-1026. PubMed ID: 33350309
[TBL] [Abstract][Full Text] [Related]
2. Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2.
Klemm T; Ebert G; Calleja DJ; Allison CC; Richardson LW; Bernardini JP; Lu BG; Kuchel NW; Grohmann C; Shibata Y; Gan ZY; Cooney JP; Doerflinger M; Au AE; Blackmore TR; van der Heden van Noort GJ; Geurink PP; Ovaa H; Newman J; Riboldi-Tunnicliffe A; Czabotar PE; Mitchell JP; Feltham R; Lechtenberg BC; Lowes KN; Dewson G; Pellegrini M; Lessene G; Komander D
EMBO J; 2020 Sep; 39(18):e106275. PubMed ID: 32845033
[TBL] [Abstract][Full Text] [Related]
3. Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease.
Hajbabaie R; Harper MT; Rahman T
Molecules; 2021 Feb; 26(4):. PubMed ID: 33672721
[TBL] [Abstract][Full Text] [Related]
4. An Updated Review on SARS-CoV-2 Main Proteinase (M
Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134
[TBL] [Abstract][Full Text] [Related]
5. The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery.
Fu Z; Huang B; Tang J; Liu S; Liu M; Ye Y; Liu Z; Xiong Y; Zhu W; Cao D; Li J; Niu X; Zhou H; Zhao YJ; Zhang G; Huang H
Nat Commun; 2021 Jan; 12(1):488. PubMed ID: 33473130
[TBL] [Abstract][Full Text] [Related]
6. Identification of potential plant-based inhibitor against viral proteases of SARS-CoV-2 through molecular docking, MM-PBSA binding energy calculations and molecular dynamics simulation.
Gogoi B; Chowdhury P; Goswami N; Gogoi N; Naiya T; Chetia P; Mahanta S; Chetia D; Tanti B; Borah P; Handique PJ
Mol Divers; 2021 Aug; 25(3):1963-1977. PubMed ID: 33856591
[TBL] [Abstract][Full Text] [Related]
7. Microbial based natural compounds as potential inhibitors for SARS-CoV-2 Papain-like protease (PLpro): a molecular docking and dynamic simulation study.
Rahul S; Sarkar A
J Biomol Struct Dyn; 2022; 40(24):13848-13858. PubMed ID: 34730069
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 Papain-Like Protease Potential Inhibitors-In Silico Quantitative Assessment.
Stasiulewicz A; Maksymiuk AW; Nguyen ML; Bełza B; Sulkowska JI
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921228
[TBL] [Abstract][Full Text] [Related]
9.
Rudrapal M; Issahaku AR; Agoni C; Bendale AR; Nagar A; Soliman MES; Lokwani D
J Biomol Struct Dyn; 2022; 40(20):10437-10453. PubMed ID: 34182889
[TBL] [Abstract][Full Text] [Related]
10. Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.
Amin SA; Banerjee S; Ghosh K; Gayen S; Jha T
Bioorg Med Chem; 2021 Jan; 29():115860. PubMed ID: 33191083
[TBL] [Abstract][Full Text] [Related]
11. Structure-based identification of SARS-CoV-2 main protease inhibitors from anti-viral specific chemical libraries: an exhaustive computational screening approach.
Bhowmick S; Saha A; Osman SM; Alasmary FA; Almutairi TM; Islam MA
Mol Divers; 2021 Aug; 25(3):1979-1997. PubMed ID: 33844135
[TBL] [Abstract][Full Text] [Related]
12. Repurposing the antibacterial drugs for inhibition of SARS-CoV2-PLpro using molecular docking, MD simulation and binding energy calculation.
Patel R; Prajapati J; Rao P; Rawal RM; Saraf M; Goswami D
Mol Divers; 2022 Aug; 26(4):2189-2209. PubMed ID: 34591234
[TBL] [Abstract][Full Text] [Related]
13. Identifying structural-functional analogue of GRL0617, the only well-established inhibitor for papain-like protease (PLpro) of SARS-CoV2 from the pool of fungal metabolites using docking and molecular dynamics simulation.
Rao P; Patel R; Shukla A; Parmar P; Rawal RM; Saraf M; Goswami D
Mol Divers; 2022 Feb; 26(1):309-329. PubMed ID: 33825097
[TBL] [Abstract][Full Text] [Related]
14. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.
Báez-Santos YM; St John SE; Mesecar AD
Antiviral Res; 2015 Mar; 115():21-38. PubMed ID: 25554382
[TBL] [Abstract][Full Text] [Related]
15. Identification of Severe Acute Respiratory Syndrome Coronavirus-2 inhibitors through in silico structure-based virtual screening and molecular interaction studies.
Azad I; Khan T; Maurya AK; Irfan Azad M; Mishra N; Alanazi AM
J Mol Recognit; 2021 Oct; 34(10):e2918. PubMed ID: 34132436
[TBL] [Abstract][Full Text] [Related]
16. Ciclesonide Inhibits SARS-CoV-2 Papain-Like Protease in Vitro.
Kiba Y; Tanikawa T; Kitamura M
Biol Pharm Bull; 2024; 47(5):965-966. PubMed ID: 38763750
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M
Ghosh A; Chakraborty M; Chandra A; Alam MP
J Mol Model; 2021 Feb; 27(3):97. PubMed ID: 33641023
[TBL] [Abstract][Full Text] [Related]
18. High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors.
Zhao Y; Du X; Duan Y; Pan X; Sun Y; You T; Han L; Jin Z; Shang W; Yu J; Guo H; Liu Q; Wu Y; Peng C; Wang J; Zhu C; Yang X; Yang K; Lei Y; Guddat LW; Xu W; Xiao G; Sun L; Zhang L; Rao Z; Yang H
Protein Cell; 2021 Nov; 12(11):877-888. PubMed ID: 33864621
[TBL] [Abstract][Full Text] [Related]
19. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV.
Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K
Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel human USP2 inhibitor and its putative role in treatment of COVID-19 by inhibiting SARS-CoV-2 papain-like (PLpro) protease.
Mirza MU; Ahmad S; Abdullah I; Froeyen M
Comput Biol Chem; 2020 Dec; 89():107376. PubMed ID: 32979815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
